Formula for traditional Chinese medicines for treating esophageal cancer and method for preparing traditional Chinese medicines

Abstract

The invention discloses a formula for traditional Chinese medicines for treating esophageal cancer. The traditional Chinese medicines in the formula comprise, by weight, 10-15 g of rabdosia rubescens,10-15 parts of herba scutellariae barbatae, 10-15 g of chelidonium majus, 10 g of radix scrophulariae, 10 g of radix astragali, 10 g of radix adenophorae, 10 g of herba dendrobii, 10 g of rhizoma pinelliae, 10 g of poria, 10 g of radix sophorae tonkinensis, 10 g of spica prunellae, 10 g of flos inulae, 10 g of radix clematidis and 10-30 g of radix glycyrrhizae. Methods for preparing and applyingthe traditional Chinese medicines which are traditional Chinese medicine compositions include soaking medicines in cold water for 50-60 minutes; adding water to allow the water level to be higher thanthe medicines by 3-5 centimeters; decocting the medicines on strong fire (big fire) before decoction is boiling, decocting the decoction on soft fire (small fire) after the decoction is boiling, slightly boiling the decoction, primarily decocting the medicines for approximately 35 minutes to obtain first decoction, and secondarily decocting the medicines for approximately 30 minutes to obtain second decoction; mixing the first decoction and the second decoction with each other to obtain mixed decoction, taking a dose of mixed decoction by two times in the morning and the evening on a daily basis. 30 doses of mixed decoction need to be taken in a treatment course. The formula and the methods have the advantages that patients need to persist in medication, and increasingly good effects canbe realized along with prolonging of the treatment course.

Description

technical field [0001] The invention belongs to a traditional Chinese medicine composition, and in particular relates to a traditional Chinese medicine formula for treating esophageal cancer and a preparation method thereof. Background technique [0002] Esophageal cancer is one of the most common malignant tumors in the world, with 456,000 new cases and more than 400,000 deaths worldwide every year. At present, surgical treatment is the main treatment for esophageal cancer in my country. Among them, 20%-25% of patients are early esophageal cancer, and the 5-year survival rate after operation is about 50%. The survival rate is only 20.64-34.00%, and most patients have metastasis or local recurrence within 3 years after operation. It can be seen that the survival rate of patients with stage IIB and stage III largely represents the effect of esophageal cancer treatment. Therefore, to improve the curative effect of esophageal cancer, in addition to early diagnosis and early ...

AI Technical Summary

Problems solved by technology

However, there is currently no effective therapeutic drug and its application method for alleviating radiotherapy and chemotherapy resistance.